HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Iomeprol

HCID 3731
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
78649-41-9
Standard SMILES
CN(C(=O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I
InChIKey
NJKDOADNQSYQEV-UHFFFAOYSA-N
Molecular formula
C17H22I3N3O8
Average molar mass
777.1 g/mol
Monoisotopic mass
776.8541

Overview

Iomeprol is a benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a glycoloyl(methyl)amino group at the 5-position. It has a role as a xenobiotic, a radioopaque medium and an environmental contaminant. It is an organoiodine compound and a benzenedicarboxamide.

Names & identifiers

Preferred name
Iomeprol
IUPAC
1-N,3-N-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-methylamino]-2,4,6-triiodobenzene-1,3-dicarboxamide
English name
IOMEPROL
Molecular formula
C17H22I3N3O8
Molecular weight
777.09

Names & synonyms

iomeprol78649-41-9IomeronIomeprolumIomeproloDTXSID1049061Iomeron 300IOMERVUE-7337N,N'-Bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(N-methylglycolamido)isophthalamide17E17JBP8LDTXCID2028987
Show more names
Iomepol.Iomeron 350ImeronImeron 300Iomeprogr.Iomeprol materialIOMEPROL USP/EP/BPC14348000 Iomeprol
E7337CHEBI:31710N,N'-bis(2,3-dihydroxypropyl)-5-[glycoloyl(methyl)amino]-2,4,6-triiodoisophthalamide1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-5-((hydroxyacetyl)methylamino)-2,4,6-triiodo-Iomeprol InjectionN,N'-bis(2,3-dihydroxypropyl)-5-(glycoloyl(methyl)amino)-2,4,6-triiodoisophthalamideRefChem:57671V08AB10

Database identifiers

CAS
78649-41-9
PubChem CID
3731
DTXSID
DTXSID1049061
ChEMBL
CHEMBL2107214
ChEBI

Properties

Computed structural properties

XLogP
-2.3
Topological polar surface area
180 Ų
Hydrogen bond donors
7
Hydrogen bond acceptors
8
Rotatable bonds
10
Heavy atoms
31
Formal charge
0
Complexity
591

Experimental & physicochemical properties

DrugsPharmaceuticals
Human Drugs · 3 items

Breast Feeding; Lactation; Milk, Human; Contrast Media; Diagnostic Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point285-291
Collision Cross Section211.2 Ų [M-H]-

Physicochemical properties

Melting point
263 · 263-265C
Boiling point
813.2 · 813.2±65.0 °C(Predicted)
Density
420 · d420 1.166; d437 1.161; d420 1.334; d437 1.329; d420 1.446; d437 1.441
refractive index
20 · nD20 1.3828; nD20 1.4327; nD20 1.4660
storage temp.
-20 °C · -20°C Freezer
solubility
DMSO (Slightly), Methanol (Slightly)
pka
11.36 · 11.36±0.46(Predicted)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Toxicology

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

hs_code
2924299090
Toxicity
LD50 (400 mgI/ml soln) i.v. in mice, rats (gI/kg): 19.9, 14.5; LD50 (370 mgI/ml soln) i.v. in dogs (gI/kg): >12.5 (Morisetti)

Chemistry & industry

Pharmacology

ATC Code · 3 items

V08AB10

V - Various

QV - Various

Protein BindingIomeprol does not bind to plasma proteins.
Pharmacodynamics · 1 item

The degree of radiographic enhancement by iomeprol is related to the iodine concentration in the tissue of interest following the administration of iomeprol. However, the exposure-response relationships and time course of pharmacodynamic response of iomeprol have not been fully characterized. At therapeutic concentrations, iomeprol was not shown to cause significant effects on the cardiovascular, central nervous, renal, and complement systems.

Mechanism of Action · 1 item

Iomeprol is a radiographic iodinated contrast agent that opacifies the vessels and body structures where the contrast agent is present following intravenous or intra-arterial administration, permitting radiographic visualization of the internal structures through attenuation of X-ray photons. In imaging of the body, iodinated contrast agents diffuse from the vessels into the extravascular space. In normal brain with an intact blood-brain barrier, the contrast agent does not diffuse into the extravascular space and contrast enhancement is generally due to the presence of contrast within the vascular space. In patients with a disrupted blood-brain barrier, the contrast agent accumulates in the extravascular space in the region of disruption.

Biological Half-LifeThe elimination half-life of iomeprol is 1.8 (0.33) hours.
Metabolism/MetabolitesIomeprol does not undergo significant metabolism.
FDA Pharmacological Classification · 6 items

17E17JBP8L

IOMEPROL

Established Pharmacologic Class [EPC] - Radiographic Contrast Agent

Mechanisms of Action [MoA] - X-Ray Contrast Activity

Iomeprol is a Radiographic Contrast Agent. The mechanism of action of iomeprol is as a X-Ray Contrast Activity.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
CHEBI:31710
UNII
17E17JBP8L
Nikkaji
J277.762B
form
Solid
color
White to Off-White
InChI
InChI=1S/C17H22I3N3O8/c1-23(9(29)6-26)15-13(19)10(16(30)21-2-7(27)4-24)12(18)11(14(15)20)17(31)22-3-8(28)5-25/h7-8,24-28H,2-6H2,1H3,(H,21,30)(H,22,31)
InChIKey
NJKDOADNQSYQEV-UHFFFAOYSA-N
SMILES
C1(C(NCC(O)CO)=O)=C(I)C(N(C(CO)=O)C)=C(I)C(C(NCC(O)CO)=O)=C1I
CAS DataBase Reference
78649 · 78649-41-9(CAS DataBase Reference)
FDA UNII
17 E17JBP8L · 17E17JBP8L
ATC code
8 AB10 · V08AB10
EPA Substance Registry System
1 · 1,3-Benzenedicarboxamide, N1,N3-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)methylamino]-2,4,6-triiodo- (78649-41-9)
HS Code
2924299090 · 2924299090
Toxicity
50 · LD50 (400 mgI/ml soln) i.v. in mice, rats (gI/kg): 19.9, 14.5; LD50 (370 mgI/ml soln) i.v. in dogs (gI/kg): >12.5 (Morisetti)

IOMEPROL INJECTION

MeSH Pharmacological ClassificationSubstances used to allow enhanced visualization of tissues.
Absorption, Distribution and Excretion · 4 items

The maximum concentration (Cmax) and area under the concentration-time curve (AUC) are doseproportional across the dose range of 250 mg iodine/kg to 1,250 mg iodine/kg body weight.

Approximately 90% of the iomeprol dose is excreted unchanged in urine within 24 hours.

The volume of distribution of iomeprol is 0.28 (0.05) L/kg. In rats, iomeprol was shown to cross the placenta and be excreted into breast milk.

The total body clearance is 0.10 (0.01) L/hr/kg.

Uses & manufacturing

UsesUse (kg) in Switzerland (2009): >1000

Applications

UsesDiagnostic aid (radiopaque medium).

Upstream & downstream products

Upstream raw materials

5-AMino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxaMide Tetraacetate5-Amino-2,4,6-triiodoisophthaloyl dichloride5-Amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamideN-DesMethyl IoMeprol5-[[2-(Acetyloxy)acetyl]amino]-2,4,6-triiodo-1,3-benzenedicarbonyl Dichloride5-Aminoisophthalic acidDimethyl sulfateIodomethane

Additional notes

DefinitionChEBI: A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a glycoloyl(methyl)amino group at the 5-position.